NEW YORK – MyCartis spinoff Antelope Dx said Tuesday it has completed a €9 million ($10.7 million) Series B financing round.
The round was led by a consortium headed by medical device private equity fund Whitefund, as well as investors from the previous Series A round. Whitefund Chairman Michel Baijot and Noshaq Investment Manager Hugues Wallemacq will join Antelope's board. The new round brings the company's total funding raised to date to €14.1 million.
Founded last year, the Ghent, Belgium-based company is developing a palm-sized diagnostic device for home testing. It plans to use the new funds to initiate clinical development of a urine-based self-test for Chlamydia trachomatis and Neisseria gonorrhoeae. The firm is also working on quantitative measurements of protein biomarkers in a finger prick blood sample, as well as a respiratory test for influenza A/B and SARS-CoV-2 requiring a single swab sample that would allow patients to test for the diseases at home.
Antelope's platform is based on lab-on-chip technology and "aims to perform high quality tests on any bodily fluid" without sample preparation. Last month, the company received a €2.2 million grant from the Flanders Agency for Innovation and Entrepreneurship to expand its testing platform to include nasal swab and blood samples.